[News Space=Reporter seungwon lee] Infurness (CEO Kwak Seong-moon), which imports and sells the expensive premium bed 'VISPRING (UK)' used by famous celebrities and tycoons, saw its sales decrease last year, operating profit increase, but net profit for the period plummeted by about 70%. Notable changes include the expansion of short-term trading securities valuation losses in 2024, a sharp increase in short-term borrowings, and a reduction in dividends. In particular, exposure of investment assets to market volatility, dependence on CEO transactions, and liquidity management burden are emergi
[News Space=Reporter seungwon lee] Since the pandemic, the number of companies with an interest coverage ratio of 1 or less, which cannot even pay interest with their operating profit, has more than doubled as large corporations' interest expenses have increased 2.4 times due to decreased operating profit and rising interest rates until last year. In particular, the number of "zombie companies" that have recorded an interest coverage ratio of 1 or less for three consecutive years has reached 20. On the 29th, the Corporate Analysis Research Institute Leaders Index (CEO Park Joo-geun) analyzed t
[News Space=Reporter seungwon lee] Volvo Cars Korea (CEO Lee Yoon-mo) saw its operating profit increase last year, but its sales and net profit decreased. This is because the deterioration in the non-operating sector's performance caused a decrease in net profit for the period. In addition, it is facing complex risks such as a high debt ratio approaching 800%, deterioration of non-operating profit and loss, strengthening of global supply chain and ESG regulations, and two legal disputes. Cash generation is even weakening to the extent that operating cash flow is negative (-KRW 1.1 billion). Vo
[News Space=Reporter seungwon lee] Daewon Pharmaceutical (CEO Baek Seung-yeol) has been hit with a 'profitability warning light' as its operating profit and net profit both declined despite sales growth last year. According to the Financial Supervisory Service's electronic disclosure system on the 20th, Daewon Pharmaceutical's consolidated sales in 2024 increased by 13.5% from 526.9 billion won the previous year to 598.1 billion won. However, operating profit, a qualitative indicator, decreased by 12.4% from 32.2 billion won the previous year to 28.2 billion won, and net profit also decreased
서울시 서초구 사평대로 140 코웰빌딩 B1, 318호 | 대표전화 : 0505-546-0505 | 팩스 : 0505-548-0505
제호 : 뉴스스페이스(NewsSpace) | 등록번호 : 서울 아 54727 | 등록일 : 2023-03-07 | 발행일 : 2023-03-07
발행·편집인 : 이현주 | 청소년보호책임자 : 김정영 | 법률자문 : 이수동 변호사(법률사무소 이수)
Copyright © 2024 뉴스스페이스(NewsSpace). All rights reserved.
UPDATE: 2025년 11월 17일 19시 10분
